Janus Henderson Group PLC lifted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 31.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 591,870 shares of the pharmaceutical company’s stock after acquiring an additional 142,895 shares during the quarter. Janus Henderson Group PLC owned approximately 0.23% of Vertex Pharmaceuticals worth $89,988,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently modified their holdings of VRTX. Achmea Investment Management B.V. increased its holdings in Vertex Pharmaceuticals by 68.0% in the second quarter. Achmea Investment Management B.V. now owns 8,668 shares of the pharmaceutical company’s stock worth $1,116,000 after purchasing an additional 3,507 shares in the last quarter. NorthCoast Asset Management LLC bought a new stake in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $782,000. Delta Lloyd Asset Management N.V. purchased a new position in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $3,285,000. Picton Mahoney Asset Management purchased a new position in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $13,077,000. Finally, Prudential Financial Inc. boosted its position in shares of Vertex Pharmaceuticals by 12.8% during the second quarter. Prudential Financial Inc. now owns 444,725 shares of the pharmaceutical company’s stock valued at $57,312,000 after buying an additional 50,350 shares during the last quarter. Institutional investors own 93.33% of the company’s stock.
In other Vertex Pharmaceuticals news, CMO Jeffrey Chodakewitz sold 3,437 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $151.64, for a total value of $521,186.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeffrey M. Leiden sold 125,000 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $141.35, for a total value of $17,668,750.00. Following the completion of the sale, the chief executive officer now owns 237,407 shares of the company’s stock, valued at approximately $33,557,479.45. The disclosure for this sale can be found here. Insiders have sold a total of 343,519 shares of company stock valued at $49,488,660 over the last 90 days. 1.80% of the stock is currently owned by company insiders.
VRTX has been the topic of several analyst reports. BidaskClub cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 19th. Jefferies Group reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, August 22nd. Vetr cut Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 price objective on the stock. in a research report on Monday, September 4th. Royal Bank of Canada started coverage on Vertex Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $175.00 price objective on the stock. Finally, Needham & Company LLC reissued a “buy” rating and issued a $195.00 price objective on shares of Vertex Pharmaceuticals in a research report on Sunday, September 17th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $173.22.
Vertex Pharmaceuticals Incorporated (VRTX) opened at $142.53 on Friday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $71.46 and a fifty-two week high of $167.85. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $35,636.54, a PE ratio of 234.85, a PEG ratio of 3.37 and a beta of 1.58.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.49. The company had revenue of $578.20 million during the quarter, compared to analysts’ expectations of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. Vertex Pharmaceuticals’s quarterly revenue was up 39.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.16 EPS. research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 0.76 earnings per share for the current fiscal year.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.